|
WDR3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.62640003873594E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4636000000845E-07 |
| Normal-vs-Stage2 |
2.100300E-03 |
| Normal-vs-Stage3 |
1.41620000171372E-08 |
| Normal-vs-Stage4 |
1.65949999963999E-07 |
| Stage1-vs-Stage2 |
3.975400E-01 |
| Stage1-vs-Stage3 |
1.258630E-01 |
| Stage1-vs-Stage4 |
1.441450E-01 |
| Stage2-vs-Stage3 |
8.286000E-02 |
| Stage2-vs-Stage4 |
8.462000E-02 |
| Stage3-vs-Stage4 |
7.888200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.32899999893965E-08 |
| Normal-vs-AfricanAmerican |
2.220100E-03 |
| Normal-vs-Asian |
2.89899999994514E-06 |
| Caucasian-vs-AfricanAmerican |
4.646800E-01 |
| Caucasian-vs-Asian |
8.136800E-01 |
| AfricanAmerican-vs-Asian |
3.749600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60650004410456E-09 |
| Normal-vs-Female |
1.5210000003929E-07 |
| Male-vs-Female |
7.996400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.80569999958169E-07 |
| Normal-vs-Age(41-60Yrs) |
1.26400000022286E-07 |
| Normal-vs-Age(61-80Yrs) |
1.17529999954513E-07 |
| Normal-vs-Age(81-100Yrs) |
8.181700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.047000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.183400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.038800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.498600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.021400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.867600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.675970E-01 |
| Classical-VS-Follicular |
5.527600E-01 |
| Classical-VS-Other |
1.343980E-01 |
| Classical-VS-Normal |
2.44830000051266E-07 |
| Tall-VS-Follicular |
3.793200E-01 |
| Tall-VS-Other |
4.190200E-01 |
| Tall-VS-Normal |
1.5012399999903E-05 |
| Follicular-VS-Other |
2.846400E-01 |
| Follicular-VS-Normal |
2.18669999999532E-05 |
| Other-VS-Normal |
1.258560E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11169999983396E-07 |
| Normal-vs-N1 |
2.75979999964093E-07 |
| N0-vs-N1 |
1.145010E-01 |
|
|
